ATE416251T1 - Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren - Google Patents

Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren

Info

Publication number
ATE416251T1
ATE416251T1 AT01946696T AT01946696T ATE416251T1 AT E416251 T1 ATE416251 T1 AT E416251T1 AT 01946696 T AT01946696 T AT 01946696T AT 01946696 T AT01946696 T AT 01946696T AT E416251 T1 ATE416251 T1 AT E416251T1
Authority
AT
Austria
Prior art keywords
gene
rsv
genes
genome
shifted
Prior art date
Application number
AT01946696T
Other languages
German (de)
English (en)
Inventor
Christine D Krempl
Peter L Collins
Brian Murphy
Ursula Buchholz
Stephen Whitehead
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE416251T1 publication Critical patent/ATE416251T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541Use of virus, viral particle or viral elements as a vector
    • C12N2760/18543Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • C12N2760/18562Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01946696T 2000-06-23 2001-06-22 Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren ATE416251T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21370800P 2000-06-23 2000-06-23

Publications (1)

Publication Number Publication Date
ATE416251T1 true ATE416251T1 (de) 2008-12-15

Family

ID=22796187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946696T ATE416251T1 (de) 2000-06-23 2001-06-22 Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren

Country Status (13)

Country Link
EP (1) EP1294858B1 (https=)
JP (1) JP2004515218A (https=)
KR (1) KR100899030B1 (https=)
CN (1) CN1468301A (https=)
AT (1) ATE416251T1 (https=)
AU (3) AU2001268709B2 (https=)
BR (1) BRPI0112276B8 (https=)
CA (1) CA2413786A1 (https=)
DE (1) DE60136811D1 (https=)
ES (1) ES2317914T3 (https=)
IL (1) IL153530A0 (https=)
MX (1) MXPA02012818A (https=)
WO (1) WO2002000693A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100354425C (zh) * 1999-07-09 2007-12-12 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN105200069A (zh) * 2015-10-16 2015-12-30 北京交通大学 基于rna聚合酶ⅰ的rsv微型复制基因组及其应用
US10953083B2 (en) * 2015-12-11 2021-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912724B1 (en) * 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Also Published As

Publication number Publication date
EP1294858A2 (en) 2003-03-26
AU2006252238A1 (en) 2007-01-25
ES2317914T3 (es) 2009-05-01
WO2002000693A2 (en) 2002-01-03
EP1294858B1 (en) 2008-12-03
KR20030045685A (ko) 2003-06-11
CN1468301A (zh) 2004-01-14
AU6870901A (en) 2002-01-08
BRPI0112276B8 (pt) 2021-05-25
DE60136811D1 (de) 2009-01-15
KR100899030B1 (ko) 2009-05-21
MXPA02012818A (es) 2003-05-14
CA2413786A1 (en) 2002-01-03
BRPI0112276B1 (pt) 2019-12-31
AU2001268709B2 (en) 2006-09-28
JP2004515218A (ja) 2004-05-27
BR0112276A (pt) 2004-02-10
WO2002000693A3 (en) 2002-09-26
IL153530A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
Lu et al. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
Ren et al. Recent vaccine development for human metapneumovirus
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
PH12019502310A1 (en) Hbv vaccine
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
PT2301572E (pt) Vacinas virais derivadas de células com níveis baixos de adn celular residual
PH12020500526A1 (en) Paramyxoviridae expression system
Cibulski et al. A novel Anelloviridae species detected in Tadarida brasiliensis bats: first sequence of a chiropteran Anellovirus
WO2010079505A3 (en) Combined measles-human papilloma vaccine
ATE416251T1 (de) Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren
CY1107786T1 (el) Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv
BR0011160A (pt) Produção de vacinas de vìrus sinciciais respiratórios quiméricos atenuados a partiir de sequências de nucleotìdeos clonados
WO2008048984A3 (en) Methods and compositions for preparing a universal influenza vaccine
BRPI0504945B8 (pt) Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
WO2011038473A8 (pt) Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos
ZA202101156B (en) New attenuated virus strain and use thereof as a vaccine
Melendi et al. Mapping and characterization of the primary and anamnestic H-2d-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
Matveev Psychological aspects of history e-learning
Sizova ECOLOGY OF SARS-CoV-2 AND INFLUENZA COINFECTION
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)
Yeh et al. Genetic characterization of the Korean LATC06 rinderpest vaccine strain
PL397433A1 (pl) Sposób wytwarzania szczepionki rekombinowanej przy uzyciu technologii DNA immunologicznego produktu leczniczego weterynaryjnego dla golebi domowych
Yuan-Chun et al. Genetic characteristics of measles virus nucleoprotein in adults in Jilin Province, China from 2001 to 2016

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties